[Isoprodiane therapy for previously untreated cavitating pulmonary tuberculosis (author's transl)].
Isoprodiane (a combination of isoniazid, prothionamide and dapsone) was given to 22 persons with open cavitating pulmonary tuberculosis. None of them had been treated before. Microscopic and cultural sputum conversion occurred within an average of 5 and 11 weeks respectively. Treatment was discontinued in five patients: as a safety measure, despite sputum conversion, on account of the extent of the process and the general condition of the patient (one case); because of side-effects (two cases, one of whom was hypersensitive to isoniazid); because the patients failed to continue with the treatment (two cases). The early results were very promising; the long-term results cannot yet be assessed. The therapy did not materially affect the haemoglobin levels.
D000293:Adolescent; D000328:Adult; D003622:Dapsone / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D007539:Isonicotinic Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011515:Prothionamide / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004338:Drug Combinations; D007539:Isonicotinic Acids; D011515:Prothionamide; D003622:Dapsone; D007538:Isoniazid
Isoniazid + Prothionamid + Dapson (Isoprodian) in der Therapie nicht vorbehandelter kavernöser Lungentuberkulosen.